| 1 |
中华医学会呼吸病学分会. 中国成人社区获得性肺炎诊断和治疗指南(2016年版)[J]. 中华结核和呼吸杂志，2016, 39(4): 253-279.
|
| 2 |
中华医学会，中华医学会杂志社，中华医学会全科医学分会，等. 成人社区获得性肺炎基层诊疗指南(2018年)[J]．中华全科医师杂志，2019, 18(2): 117-126.
|
| 3 |
刘凯雄，瞿介明. 关于《成人社区获得性肺炎基层诊疗指南(2018年)》的几点说明[J]. 中华全科医师杂志，2019, 18(2): 101-103.
|
| 4 |
Muller MP, Mcgeer AJ, Hassan K, et al. Evaluation of pneumonia severity and acute physiology scores to predict ICU admission and mortality in patients hospitalized for influenza[J]. PLoS One, 2010, 5(3): e9563.
|
| 5 |
Shi SJ, Li H, Liu M, et al. Mortality prediction to hospitalized patients with influenza pneumonia：PO2/FiO2 combined lymphocyte count is the answer[J]. Clin Respir J, 2017, 11(3): 352-360.
|
| 6 |
Julian-Jimenez A, Gonzalez-Castillo J, Candel Gonzalez FJ. When, where and how should a patient with community acquired pneumonia be admitted？[J]. Rev Clin Esp(Barc), 2013, 213(2): 99-107.
|
| 7 |
Salih W, Schembri S, Chalmers JD. Simplification of the IDSA/ATS criteria for sever CAP using meta-analysis and observational data[J]. Eur Respir J, 2014, 43(3): 842-851.
|
| 8 |
Mulrennan S, Tempone SS, Ling IT, et al. Pandemic influenza(H1N1) 2009 pneumonia：CURB-65 score for predicting severity and nasopharyngeal sampling for diagnosis are unreliable[J]. PLoS One, 2010, 5(9): e12849.
|
| 9 |
Chen L, Zhou F, Li H, et al. Disease characteristics and management of hospitalized adolescents and adults with community-acquired pneumonia in China: a retrospective multicentre survey[J]. BMJ Open, 2018, 8: e18709.
|
| 10 |
Guo LX, Wei D, Zhang XX, et al. Clinical features predicting mortality risk in patients with viral pneumonia: The MuLBSTA score[J]. Front Microbiol, 2019, 10: 2752.
|
| 11 |
Tao LL, Hu BJ, He LX, et al. Etiology and antimicrobial resistance of community-acquired pneumonia in adult patients in China[J]. Chinese Med J, 2012, 125(17): 2967-2972.
|
| 12 |
Ali AE, Celestino P, Abid B, et al. Microbiology of sever aspiration pneumonia in institutionalized elderly[J]. Am J Respir Criti Care Med, 2003, 167(12): 1650-1654.
|
| 13 |
李 洋，石志红，杨 岚，等. 免疫损害宿主肺炎病原学分布特征及耐药情况分析[J]. 西南交通大学学报(医学版), 2016, 37(3): 423-427.
|
| 14 |
Zhu YG, Tang XD, Lu YT, et al. Contemporary situation of community-acquired pneumonia in China: A systematic review[J]. J Transl Intern Med, 2018, 6(1): 26-31.
|
| 15 |
Afshinnekoo E, Chou C, Alexander N, et al. Precision metagenomics：rapid metagenomic analyses for infectious disease diagnostics and public health surveillance[J]. J Biomol Tech, 2017, 28(1): 40-45.
|
| 16 |
Grumaz S, Stevens P, Grumaz C, et al. Next-generation sequencing diagnostics of bacteremia in septic patients[J]. Genome Med, 2016, 8(1): 73.
|
| 17 |
Long Y, Zhang Y, Gong Y, et al. Diagnosis of sepsis with cell-free DNA by next-generation sequencing technology in ICU patients[J]. Arch Med Res, 2016, 47(5): 365-371.
|
| 18 |
刘又宁. 我国成人社区获得性肺炎诊断和治疗指南的沿革与进步[J]. 中华结核和呼吸杂志，2018, 41(4): 241-243.
|
| 19 |
刘又宁. 糖皮质激素用于治疗社区获得性肺炎的是与非[J]. 中华结核和呼吸杂志，2016, 39(11): 833-834.
|
| 20 |
Chen RC, Tang XP, Tan SY, et al. Treatment of sever acute respiratory syndrome with glucosteroids：the Guangzhou experience[J]. Chest, 2006, 129(6): 1441-1452.
|
| 21 |
Yam LY, Lau AC, Lai FY, et al. Corticosteroid treatment of severe acute respiratory syndrome in Hong Kong[J]. J Infect, 2007, 54(1): 28-39.
|
| 22 |
Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects[J]. PLoS Med, 2006, 3(9): e343.
|
| 23 |
Arabi YM, Mandourah Y, Al-Hameed F, et al. Corticosteroid therapy for critically ill patients with middle east respiratory syndrome[J]. Am J Respir Crit Care Med, 2018, 197(6): 757-767.
|
| 24 |
Lansbury LE, Rodrigo C, Leonardi-Bee J, et al. Corticosteroids as adjunctive therapy in the treatment of influenza：an updated Cochrane systematic review and meta-analysis[J]. Crit Care Med, 2020, 48(2): e98-e106.
|
| 25 |
Siemieniuk RA, Meade MO, Alonso-Coello P, et al. Corticosteroid therapy for patients hospitalized with community-acquired pneumonia：a systematic review and meta-analysis[J]. Ann Intern Med, 2015, 163(7): 519-28.
|
| 26 |
中华人民共和国国家卫生健康委员会．新型冠状病毒肺炎诊疗方案(试行第六版)[EB/OL]．(2020-02-19)．
URL
|
| 27 |
赵建平，胡 轶，杜荣辉，等. 新型冠状病毒肺炎糖皮质激素使用的建议[J]. 中华结核和呼吸杂志，2020, 43(3): 183-184.
|
| 28 |
李太生，曹 玮，翁 利，等. 北京协和医院关于"新型冠状病毒感染的肺炎"诊疗建议方案(V2.0)[J]. 中华内科杂志，2020, 59(3): 186-188.
|
| 29 |
军队前方专家组. 军队支援湖北医疗队新型冠状病毒病诊疗方案(试行第二版)[J]. 中华结核和呼吸杂志，2020, (5): 414-420.
|
| 30 |
The WHO rapid evidence appraisal for COVID-19 therapies (REACT) working group. Association between administration of systemic corticosteroids and mortality among critically Ⅲ patients with COVID-19: A Meta-analysis[J]. JAMA, 2020, 324(13): 1330-1341.
|
| 31 |
雷 翔，郑 蕊，李 楠，等. 血必净注射液治疗重症肺炎系统评价的再评价[J]. 中国中西医结合急救杂志，2016, 23(2): 133-137.
|
| 32 |
Song YL, Yao C, Yao YM, et al. Xuebijing injection versus placebo for critically III patients with sever community-acquired pneumonia：a randomized controlled trial[J]. Criti Care Med, 2019, 47(9): e735-e743.
|